1、报告期内，公司未发生控股股东及其他关联方占用公司资金的情况，也 不存在以前年度发生并延续到报告期内的占用公司资金的情况。 2、报告期内，公司及控股子公司担保总额为不超过人民币 8 亿元，截至本 报告期末，尚在有效期内的担保总额为不超过 8 亿元（均为上市公司及全资子公 司为全资子公司提供之担保）。上述担保均已履行相应的审议程序，为公司正常 经营所需，除上述对外担保外，上市公司及控股子公司不存在其他对外担保，不 存在对合并报表外单位提供担保的情况，亦不存在涉及债务逾期、诉讼的担保及 因被判决而应承担责任的担保。 独立董事：李耀、张大可、胡诗阳 成都市贝瑞和康基因技术股份有限公司独立董事 独立董事关于公司控股股东及其他关联方占用公司资金、公司 对外担保情况的专项说明和独立意见 根据《中华人民共和国公司法》、《深圳证券交易所股票上市规则》、《关于在 上市公司建立独立董事制度的指导意见》等法律、法规和规范性文件以及《成都 市贝瑞和康基因技术股份有限公司章程》、《独立董事制度》等有关规定，我们作 为成都市贝瑞和康基因技术股份有限公司（以下简称"公司"、"上市公司"）的 独立董事，对公司控股股东及其他关联方占用公司资 ...

Financial Performance - The company's revenue for Q1 2023 was ¥280,207,812.40, a decrease of 10.62% compared to ¥313,494,177.23 in the same period last year[5] - The net loss attributable to shareholders was ¥20,738,437.15, representing a 73.86% increase from a loss of ¥11,928,399.03 in the previous year[5] - The company's basic and diluted earnings per share were both -¥0.06, a decline of 50.00% from -¥0.04 in the same period last year[5] - Net loss for Q1 2023 was CNY 20,110,444.46, compared to a net loss of CNY 12,217,400.42 in Q1 2022, indicating a worsening of 64.5%[18] - The company reported a total comprehensive loss of CNY 22,543,430.36 for Q1 2023, compared to a loss of CNY 13,266,230.07 in Q1 2022[18] Cash Flow - The net cash flow from operating activities improved by 17.68%, amounting to -¥41,528,166.03 compared to -¥50,449,164.21 in the prior year[5] - The company's cash flow from operating activities was CNY 292,298,259.97 in Q1 2023, down from CNY 382,947,930.27 in Q1 2022, representing a decline of 23.6%[20] - The net cash flow from financing activities was -¥7,632,206.64, compared to -¥94,916.69 in Q1 2022, showing a significant deterioration[22] - The total cash outflow from operating activities was 337,608,941.20, compared to 435,891,737.57 in Q1 2022, indicating a reduction of about 22.5%[21] - Total cash inflow from investment activities was 6,484,002.22, while cash outflow was 2,001,375.48, resulting in a net cash flow of 4,482,626.74, compared to -26,194,475.14 in the same period last year[21] Assets and Liabilities - Total assets as of March 31, 2023, were ¥3,170,793,442.57, a decrease of 0.94% from ¥3,200,862,871.74 at the end of the previous year[5] - The total liabilities as of Q1 2023 were CNY 864,689,294.83, slightly down from CNY 871,535,028.84 in the previous quarter[18] - The total equity attributable to shareholders decreased by 1.04% to ¥2,277,535,038.01 from ¥2,301,386,725.87 at the end of the previous year[5] - The company's long-term equity investments decreased to CNY 104,727,156.18 from CNY 112,536,596.20, a decline of approximately 7%[14] Operational Efficiency - Total operating costs for Q1 2023 were CNY 282,899,819.60, down from CNY 309,299,721.50 in the previous year, reflecting a reduction of 8.5%[17] - Research and development expenses decreased to CNY 20,680,673.90 in Q1 2023 from CNY 26,127,459.15 in Q1 2022, a reduction of 21.0%[17] - The company experienced a 35.10% decrease in prepayments, which fell to ¥22,284,411.38 from ¥34,338,731.67[8] Income and Other Financial Metrics - Other income decreased by 37.10%, totaling ¥1,412,798.46 compared to ¥2,246,212.02 in the same period last year[8] - The company reported a significant increase in credit impairment losses, which rose by 157.90% to -¥6,670,255.61 from -¥2,586,347.73 in the previous year[8] - The company received tax refunds amounting to 231,446.97, compared to 23,868.88 in the previous year, marking a substantial increase[21] - The company paid 16,170,026.56 in taxes, down from 22,336,177.06 in Q1 2022, reflecting a decrease of approximately 27.6%[21] Strategic Focus - The report indicates a strategic focus on maintaining liquidity while managing receivables and inventory levels effectively[13] - The company is actively managing its financial assets, with trading financial assets remaining stable at CNY 4,505,243.01[14]

Business Focus and Strategy - Berry Genomics reported a significant shift in its main business focus from automotive parts to high-throughput sequencing-based genetic testing services and equipment sales following a major asset restructuring completed in August 2017[22]. - The company aims to expand its market presence, leveraging advancements in non-invasive prenatal testing and other genetic testing technologies[5]. - The company is positioned within a key emerging industry, as highlighted in the "14th Five-Year Plan" which emphasizes health technology and biotechnological advancements[34]. - The company aims to become a gene technology firm focused on clinical commercialization and health big data development, leveraging existing testing platforms to accumulate genetic data[98]. - The company plans to enhance its existing non-invasive products and services to assist clinical decision-making in precision medicine[99]. Financial Performance - The company's operating revenue for 2022 was ¥1,368,007,211.88, a decrease of 3.81% compared to ¥1,422,180,921.29 in 2021[24]. - The net profit attributable to shareholders was -¥254,778,590.81, representing a decline of 129.91% from -¥110,818,562.80 in the previous year[24]. - The cash flow from operating activities was ¥21,178,809.92, down 77.48% from ¥94,031,452.65 in 2021[24]. - The basic and diluted earnings per share were both -¥0.82, a decrease of 164.52% compared to -¥0.31 in 2021[24]. - The company reported a total revenue of 1,055.04 million CNY, representing a 2.25% increase compared to the previous year[172]. Research and Development - The company has committed to ongoing research and development in new products and technologies to enhance its service offerings in genetic testing[5]. - The company is actively involved in the development of new technologies and products, including third-generation sequencing techniques for various genetic disorders, enhancing diagnostic accuracy[40]. - The company has developed over 1 PB of gene data annually, enhancing its capabilities in clinical information interpretation and artificial intelligence algorithms[54]. - The company has established a robust research service platform utilizing leading sequencing technologies, including Illumina NovaSeq6000 and PacBio Sequel, to support various scientific research fields[43]. Market Trends and Opportunities - The gene sequencing industry is rapidly growing, supported by national policies and increasing public awareness of disease prevention[34]. - The high-throughput sequencing market is expected to continue rapid growth, driven by decreasing sequencing costs and increasing application scenarios in reproductive health, oncology, and consumer-grade genetic testing[37]. - The Beijing Medical Insurance Bureau included 16 assisted reproductive technologies, such as artificial insemination and embryo transfer, in the Class A reimbursement scope, which is expected to enhance the penetration of gene sequencing products and services[37]. Corporate Governance and Management - The company operates independently from its controlling shareholders, ensuring no overlap in business operations or financial dealings[111]. - The company has established a complete independent financial system, with separate financial management and decision-making processes, ensuring no interference from shareholders[113]. - The company has a robust organizational structure with clearly defined responsibilities, operating independently from its major shareholders[113]. - The company has conducted multiple shareholder meetings, with participation rates of 32.44% and 19.60% in the respective meetings held in 2022[114]. Employee and Talent Management - The total number of employees at the end of the reporting period is 1,438, with 1,434 in major subsidiaries[137]. - The educational background of employees includes 21 with PhDs, 309 with master's degrees, and 724 with bachelor's degrees, reflecting a highly educated workforce[137]. - The company has established a competitive salary system to align with business development and market standards, integrating performance management with salary incentives[138]. - The company has a detailed regulation on related party transactions, ensuring strict compliance and risk control[146]. Risks and Challenges - Future operational risks and challenges are outlined in the management discussion, emphasizing the need for investor awareness regarding potential uncertainties[5]. - The company faces risks from industry policy changes, intensified market competition, and potential declines in service prices[101]. - The rapid expansion of accounts receivable poses a risk of bad debts, which could impact the company's operational development[104]. - The company is exposed to financial risks, including potential declines in gross margin due to market competition and regulatory uncertainties[104]. Product and Service Offerings - The company focuses on gene detection services based on high-throughput sequencing technology, targeting areas such as reproductive health, genetic disease detection, and tumor detection[38]. - The company provides comprehensive genetic testing services covering three levels of birth defect prevention, including carrier screening for 153 diseases and pre-implantation genetic testing[39]. - The company offers non-invasive prenatal testing (NIPT) for chromosomal aneuploidy screening and a more advanced NIPT Plus for 100 chromosomal and genomic diseases[39]. - The company has developed a comprehensive cancer screening product "Laisining" for liver cancer, validated by a prospective cohort study involving over 10,000 participants, and included in the national early screening strategy[42]. Shareholder and Equity Information - The company reported a total shareholding of 58.45 million shares at the end of the reporting period, down from 64.11 million shares at the beginning, indicating a decrease of approximately 8.3%[117]. - The largest shareholder, Chengdu Tianxing Instrument (Group) Co., Ltd., holds 12.41% of the shares, totaling 44,002,000 shares, with no changes during the reporting period[199]. - The total number of shareholders at the end of the reporting period was 41,358, with a slight decrease from the previous month[198]. - The company has maintained a consistent shareholder base without any significant changes in ownership during the reporting period[200].

Group 1: Restructuring Overview - The restructuring is led by the actual controller, with the project being selected after thorough comparison [2] - The actual controller has a dedicated team for related projects [2] - The restructuring aims to develop a dual-main business model, contingent on the future development of both business segments [3] Group 2: Old Ken Medical's Operations - Old Ken Medical withdrew its IPO application in May 2013 due to market changes and strategic needs [3] - The company is collaborating with the UK New Helix Group to establish a nationwide medical disinfection service outsourcing system [3] - The business performance of Old Ken Medical in January and February of this year has been reported as good [4] Group 3: Management and Financing Post-Reorganization - Post-reorganization, Liu Xia is proposed to be nominated as a candidate for the board of directors and to serve as the deputy general manager of Tianxing Instrument [4] - Daily operations of Old Ken Medical will primarily be managed by its own team, with Tianxing Instrument appointing directors and financial leaders [4] - Financing will mainly support Old Ken Medical, while Tianxing Instrument's significant expenditures will be related to relocation and new factory construction [4] Group 4: Risks and Future Plans - The reorganization faces risks such as regulatory approval, integration challenges, and inherent risks of Old Ken Medical [4][5] - The timeline for completing the reorganization is uncertain and depends on the China Securities Regulatory Commission's review [4][5]

证券代码：000710 证券简称：天兴仪表 编号：2015-04 成都天兴仪表股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 大成基金：李林益 | | | 人员姓名 | 博时基金：甘传琦 | | | 时间 | 2015 年 4 月 22 日 | | | 地点 | 董秘办公室 | | | 上市公司接待人 | 董事会秘书：叶秀松 | | | 员姓名 | 证券事务代表：左炯 | | | 投资者关系活动 | 1. | 天兴仪表车用零部件这一块业务一年有多少利润？ | | 主要内容介绍 | | 近年由于主 ...

证券代码：000710 证券简称：天兴仪表 编号：2015-02 成都天兴仪表股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|------------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 华创证券有限责任公司：彭婷 | | | 人员姓名 | | | | 时间 | 2015 年 3 月 26 日 | | | 地点 | 董秘办公室 | | | 上市公司接待人 | 董事会秘书：叶秀松 | | | 员姓名 | 证券事务代表：左炯 | | | | 1. | 天兴集团股权被冻结对公司重组的影响？ | | | | 天兴集团所持被冻结的股份在冻结 ...

Group 1: Company Overview - Chengdu Tianxing Instrument Co., Ltd. focuses on the development, production, and sales of hospital infection control equipment and provides comprehensive solutions for Central Sterile Supply Departments (CSSD) [3] - The company will maintain dual business operations in automotive instruments and hospital infection control equipment after restructuring [3][4] Group 2: Restructuring and Business Strategy - The restructuring plan is currently under review by the China Securities Regulatory Commission, and no new projects are being considered at this time [4] - The major shareholder's frozen shares do not affect the company's normal operations, and efforts are being made to resolve financial disputes [4][5] - Tianxing Group holds a controlling stake of 58.86% in Tianxing Instrument, with a market value of approximately 1.188 billion yuan as of March 6, 2015 [4][5] Group 3: Management and Operations - Post-restructuring, the original management team of Aoken Medical will continue to manage daily operations, with Tianxing Instrument appointing directors and financial leaders [5] - Aoken Medical has ongoing contracts and orders, details of which are available in the company's public announcements [5]

Group 1: Company Restructuring and Debt Situation - The company has temporarily withdrawn its major asset restructuring application due to unresolved issues regarding the freezing of shares held by the controlling shareholder [2] - As of May 27, 2015, the China Securities Regulatory Commission issued a notice to terminate the review of the company's administrative license application [2] - The controlling shareholder holds 88.96 million shares, of which 79.02 million shares are currently frozen due to a financial loan dispute involving approximately 278 million yuan, nearing 300 million yuan with interest [2] Group 2: Business Operations and Future Prospects - Despite poor operational performance, the company maintains a clean financial record without external guarantees or contingent liabilities, primarily relying on bank loans [2] - If relocation compensation funds are fully in place, the company's financial pressure will ease, leading to a reduction in debt [3] - The company is exploring potential cooperation with other firms if the share freezing issue remains unresolved in the short term [3] - The automotive instrument industry is facing significant challenges, while the medical equipment sector shows higher profit margins and promising prospects [3] - The timeline for restructuring outcomes remains uncertain, dependent on the resolution of the share freezing issue and the willingness of potential partners to wait [3]

编号：2015-12 证券代码：000710 证券简称：天兴仪表 成都天兴仪表股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|----------------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | 景顺长城基金管理有限公司：刘晓明 | | | 人员姓名 | 长城基金管理有限公司：谭小兵 | | | 时间 | 2015 年 12 月 1 日 | | | | | | | 地点 | 董秘办公室 | | | 上市公司接待人 | 董事会秘书：顾中国 | | | 员姓名 | 证券事务代表：左炯 | | | | 1. | 公司未来转型是否主要考虑医疗方向？ | | 投资者 ...

编号：2015-11 证券代码：000710 证券简称：天兴仪表 成都天兴仪表股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动 类别 | √ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 上海理成资产管理有限公司：张伟 | 汇添富基金管理股份有限公司：林小伟 | | 时间 | 2015 年 11 月 2 ...